PARP1 and ovarian cancer: The introduction in the ovarian cancer (OC) therapeutic algorithm of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) in both recurrent and first-line setting has notably improved survival outcomes of these patients.1